CSB 2.008 Note
961.16 (8) (b) An immediate precursor to fentanyl, including all of the following:
CSB 2.008 Note
1. 4-anilino-N-phenethyl-4-piperidine, commonly known as ANPP.
CSB 2.008 Note
2. N-phenyl-N-(piperidin-4-yl)propionamide, commonly known as norfentanyl.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register June 2020 No. 774, eff. 6-29-20;
CR 20-078: cr.
Register July 2021 No. 787, eff. 8-1-21.
CSB 2.008 Note
CSB 2.77 Scheduling of flualprazolam. Section
961.20 (2) (ef), Stats., is created to read:
CSB 2.008 Note
961.20 (2) (ef) Flualprazolam;
CSB 2.008 History
History:
EmR1037: emerg. cr., eff. 10-27-20;
CR 20-078: cr.
Register July 2021 No. 787, eff. 8-1-21; correction made under s.
35.17, Stats.,
Register July 2021 No. 787.
CSB 2.008 Note
CSB 2.78 Addition of crotonyl fentanyl to schedule I. Section
961.14 (2) (nd) 9m., Stats., is created to read:
CSB 2.008 Note
961.14 (2) (nd) 9m. Crotonyl Fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2- enamide);
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register November 2020 No. 779, eff. 11-23-20;
CR 22-011: cr.
Register June 2023 No. 810, eff. 7-1-23; correction made under s.
35.17, Stats.,
Register June 2023 No. 810.
CSB 2.008 Note
CSB 2.79 Addition of remimazolam to schedule IV. Section
961.20 (2) (mo), Stats., is created to read:
CSB 2.008 Note
961.20 (2) (mo) Remimazolam;
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register November 2020 No. 779, eff. 11-23-20;
CR 22-014: cr.
Register June 2023 No. 810, eff. 7-1-23; correction made under s.
35.17, Stats.,
Register June 2023 No. 810.
CSB 2.008 Note
CSB 2.80 Scheduling of oliceridine. Section
961.16 (3) (ta), Stats., is created to read:
CSB 2.008 Note
961.16 (3) (ta) Oliceridine;
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register December 2020 No. 780, eff. 12-14-20;
CR 21-098: cr.
Register August 2022 No. 800, eff. 9-1-22.
CSB 2.008 Note
CSB 2.81 Addition of brorphine to schedule I. Section
961.14 (2) (et), Stats., is created to read:
CSB 2.008 Note
961.14 (2) (et) Brorphine;
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register May 2021 No. 785, eff. 4-26-21; correction made under s.
35.17, Stats.,
Register May 2021 No. 785;
CR 22-016: cr.
Register June 2023 No. 810, eff. 7-1-23; correction made under s.
35.17, Stats.,
Register June 2023 No. 810.
CSB 2.008 Note
CSB 2.82 Addition of Serdexmethylphenidate to schedule IV. Section
961.20 (2m) (em), Stats., is created to read:
CSB 2.008 Note
961.20 (2m) (em) Serdexmethylphenidate.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register July 2021 No. 787, eff. 7-12-21;
CR 22-032: cr.
Register June 2023 No. 810, eff. 7-1-23.
CSB 2.008 Note
CSB 2.83 Addition of ten (10) fentanyl-related substances to schedule I. Section
961.14 (2) (nd) 21.,
22.,
23.,
24.,
25.,
26.,
27.,
28.,
29., and
30., Stats., is created to read:
CSB 2.008 Note
961.14 (2) (nd) 21. N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide (2'-fluoro ortho-fluorofentanyl; 2'-fluoro 2-fluorofentanyl);
CSB 2.008 Note
22. N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide (4'-methyl acetyl fentanyl);
CSB 2.008 Note
23. N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide (b'-phenyl fentanyl; beta'-Phenyl fentanyl; 3-phenylpropanoyl fentanyl);
CSB 2.008 Note
24. N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide (
b-methyl fentanyl);
CSB 2.008 Note
25. N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (ortho-fluorobutyryl fentanyl; 2-fluorobutyryl fentanyl);
CSB 2.008 Note
26. N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide (ortho-methyl acetylfentanyl; 2-methyl acetylfentanyl);
CSB 2.008 Note
27. 2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide (ortho-methyl methoxyacetylfentanyl; 2-methyl methoxyacetyl fentanyl);
CSB 2.008 Note
28. N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (para-methylfentanyl; 4-methylfentanyl);
CSB 2.008 Note
29. N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide (phenyl fentanyl; benzoyl fentanyl);
CSB 2.008 Note
30. N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide (thiofuranyl fentanyl; 2-thiofuranyl fentanyl; thiophene fentanyl).
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register July 2021 No. 787, eff. 7-19-21; correction made under s.
35.17, Stats.,
Register July 2021 No. 787;
CR 22-033: cr.
Register June 2023 No. 810, eff. 7-1-23.
CSB 2.008 Note
CSB 2.84 Addition of alfaxalone to schedule IV. (1) Section 961.20 (2) (a), Stat., is repealed and recreated to read:
CSB 2.008 Note
961.20 (2) (a) Alfaxalone;
CSB 2.008 Note
961.20 (2) (ak) Alprazolam;
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register July 2021 No. 787, eff. 7-19-21; correction in numbering made under s.
13.92 (4) (b) 1, Stats., and correction made under s.
35.17, Stats.,
Register July 2021 No. 787;
CR 22-034: cr.
Register June 2023 No. 810, eff. 7-1-23; correction in numbering made under s.
13.92 (4) (b) 1, Stats., and correction made under s.
35.17, Stats.,
Register June 2023 No. 810.
CSB 2.008 Note
CSB 2.85 Excluding 6-beta-naltrexol from schedule II. Section
961.16 (2) (a), Stats., is amended to read:
CSB 2.008 Note
961.16 (2) (a) Opium and substances derived from opium, and any salt, compound, derivative or preparation of opium or substances derived from opium. Apomorphine, dextrorphan, nalbuphine, butorphanol, naldemedine, nalmefene, naloxegol, naloxone, 6-beta-naltrexol, and naltrexone and their respective salts and the isoquinoline alkaloids of opium and their respective salts are excluded from this paragraph. The following substances, and any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register July 2021 No. 787, eff. 7-19-21; correction made under s.
35.17, Stats.,
Register July 2021 No. 787;
CR 22-035: cr.
Register June 2023 No. 810, eff. 7-1-23.
CSB 2.008 Note
CSB 2.86 Addition of fospropofol to schedule IV. Section
961.20 (2) (en), Stats., is created to read:
CSB 2.008 Note
961.20 (2) (en) Fospropofol;
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register July 2021 No. 787, eff. 7-19-21; correction made under s.
35.17, Stats.,
Register July 2021 No. 787;
CR 22-036: cr.
Register June 2023 No. 810, eff. 7-1-23; correction made under s.
35.17, Stats.,
Register June 2023 No. 810.
CSB 2.008 Note
CSB 2.87 Addition of embutramide to schedule III. Section
961.18 (3) (bm), Stats., is created to read:
CSB 2.008 Note
961.18 (3) (bm) Embutramide;
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register July 2021 No. 787, eff. 7-19-21; correction made under s.
35.17, Stats.,
Register July 2021 No. 787;
CR 22-037: cr.
Register June 2023 No. 810, eff. 7-1-23; correction made under s.
35.17, Stats.,
Register June 2023 No. 810.
CSB 2.008 Note
CSB 2.88 Addition of lacosamide to schedule V. Section
961.22 (10), Stats., is created to read:
CSB 2.008 Note
961.22 (10) Lacosamide.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register July 2021 No. 787, eff. 7-19-21;
CR 22-039: cr.
Register June 2023 No. 810, eff. 7-1-23.
CSB 2.008 Note
CSB 2.89 Addition of perampanel to schedule III. Section
961.18 (3) (fm), Stats., is created to read:
CSB 2.008 Note
961.18 (3) (fm) Perampanel.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register July 2021 No. 787, eff. 7-19-21; correction made under s.
35.17, Stats.,
Register July 2021 No. 787;
CR 22-038: cr.
Register June 2023 No. 810, eff. 7-1-23; correction made under s.
35.17, Stats.,
Register June 2023 No. 810.
CSB 2.008 Note
CSB 2.90 Transfer of 1-phenylcyclohexylamine and 1-piperidinocyclohexanecarbonitrile, immediate precursors to phencyclidine, also known as PCP, from schedule I to schedule II. Section
961.16 (8) (c), Stats., is created to read:
CSB 2.008 Note
961.16 (8) (c) Immediate precursors to phencyclidine, also known as PCP:
CSB 2.008 Note
1. 1-phenylcyclohexylamine.
CSB 2.008 Note
2. 1-piperidinocyclohexanecarbonitrile.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register July 2021 No. 787, eff. 7-19-21; correction made under s.
35.17, Stats.,
Register July 2021 No. 787;
CR 22-040: cr.
Register June 2023 No. 810, eff. 7-1-23.
CSB 2.008 Note
CSB 2.91 Addition of 4,4'-Dimethylaminorex to schedule I. Section
961.14 (7) (cm), Stats., is created to read:
CSB 2.008 Note
961.14 (7) (cm) 4,4'-Dimethylaminorex.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register September 2021 No. 789, eff. 9-27-21;
CR 22-054: cr.
Register June 2023 No. 810, eff. 7-1-23.
CSB 2.008 Note
CSB 2.92 Addition of thirty-five (35) Anabolic Steroids to schedule III. Section 961.18 (7), Stats., is repealed and recreated to read:
CSB 2.008 Note
961.18 (7) ANABOLIC STEROIDS. Unless specifically excepted or listed in another schedule, any material, compound, mixture, or preparation containing any quantity of any of the following anabolic steroids, including any of their esters, ethers, isomers, esters or ethers of isomers, salts and salts of esters or ethers, isomers and esters or ethers of isomers that are theoretically possible within the specific chemical designation. Except such terms do not include an anabolic steroid that is expressly intended for administration through implants to cattle or other nonhuman species and that has been approved by the Secretary of Health and Human Services for such administration. If any person prescribes, dispenses, or distributes such steroid for human use, the person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this section:
CSB 2.008 Note
(a) 3beta,17-dihydroxy-5alpha-androstane.
CSB 2.008 Note
(ag) 3alpha,17beta-dihydroxy-5alpha-androstane.
CSB 2.008 Note
(ar) 5alpha-androstan-3,17-dione.
CSB 2.008 Note
(b) 1-androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1-ene; 3alpha,17beta-dihydroxy-5alpha-androst-1-ene).
CSB 2.008 Note
(bg) 4-androstenediol.
CSB 2.008 Note
(br) 5-androstenediol.
CSB 2.008 Note
(c) 1-androstenedione.
CSB 2.008 Note
(cg) 4-androstenedione.
CSB 2.008 Note
(cr) 5-androstenedione.
CSB 2.008 Note
(d) Bolasterone.
CSB 2.008 Note
(dg) Boldenone.
CSB 2.008 Note
(dr) Boldione.
CSB 2.008 Note
(e) Calusterone.
CSB 2.008 Note
(eg) 4-chlorotestosterone, which is also called clostebol.
CSB 2.008 Note
(er) Dehydrochloromethyltestosterone.
CSB 2.008 Note
(f) Desoxymethyltestosterone.
CSB 2.008 Note
(fg) Delta1-dihydrotestosterone.
CSB 2.008 Note
(fr) 4-dihydrotestosterone, which is also called stanolone.
CSB 2.008 Note
(g) Drostanolone.
CSB 2.008 Note
(gg) Ethylestrenol.
CSB 2.008 Note
(gr) Fluoxymesterone.
CSB 2.008 Note
(h) Formebulone, which is also called fromebolone.
CSB 2.008 Note
(hg) Furazabol.
CSB 2.008 Note
(hr) 13beta-ethyl-17beta-hydroxygon-4-en-3-one.